Genmab Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 3,244

Employees

  • Stock Symbol
  • GMAB

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $508.98
  • (As of Friday Closing)

Genmab General Information

Description

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Contact Information

Website
www.genmab.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Carl Jacobsens Vej 30
  • 2500 Valby
  • Denmark
+45 70
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
CSE
Vertical(s)
Corporate Office
  • Carl Jacobsens Vej 30
  • 2500 Valby
  • Denmark
+45 70

Genmab Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genmab Stock Performance

As of 20-Nov-2026, Genmab’s stock price is $508.98. Its current market cap is $31.4B with 61.7M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$508.98 $513.27 $235.11 - $590.49 $31.4B 61.7M 158K $11.91

Genmab Financials Summary

As of 30-Sep-2026, Genmab has a trailing 12-month revenue of $4.3B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 25,599,225 16,396,305 10,972,474 16,931,427
Revenue 4,296,000 3,720,000 3,121,000 2,390,000
EBITDA 1,135,000 1,198,000 1,260,000 728,000
Net Income 729,000 963,000 1,133,000 631,000
Total Assets 12,936,000 12,873,000 6,414,000 5,232,000
Total Debt 5,198,000 5,426,000 144,000 114,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Genmab Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Genmab‘s full profile, request access.

Request a free trial

Genmab Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Ge
Biotechnology
Valby, Denmark
3,244 As of 2026

Hayward, CA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Genmab Competitors (74)

One of Genmab’s 74 competitors is Arcus Biosciences, a Formerly VC-backed company based in Hayward, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arcus Biosciences Formerly VC-backed Hayward, CA
Vor Biopharma Formerly VC-backed Boston, MA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Alector Formerly VC-backed South San Francisco, CA
Symphogen Formerly VC-backed Ballerup, Denmark
You’re viewing 5 of 74 competitors. Get the full list »

Genmab Patents

Genmab Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026207043-A1 Cancer treatment with an antibody drug conjugate Pending 25-Mar-2025
WO-2025242827-A1 Bispecific antibody against pd-l1 and cd137 in combination therapy Pending 22-May-2024
EP-4644413-A1 Binding agents having altered fc-mediated effector functions Pending 03-May-2024
WO-2025228844-A1 Binding agents having altered fc-mediated effector functions Pending 03-May-2024
WO-2025228542-A1 Method for co-expression of a plurality of antibodies Pending 03-May-2024 C07K16/00
To view Genmab’s complete patent history, request access »

Genmab Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Genmab Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Genmab‘s full profile, request access.

Request a free trial

Genmab Investments & Acquisitions (6)

Genmab’s most recent deal was a Merger/Acquisition with Merus for . The deal was made on 12-Dec-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Merus 12-Dec-2025 Merger/Acquisition Drug Discovery
ProfoundBio 21-May-2024 Merger/Acquisition Drug Discovery
CureVac 21-Jul-2020 Later Stage VC Drug Discovery
iDD Biotech (antibody assets) 18-Mar-2015 Corporate Asset Purchase Buildings and Property
PDL BioPharma (Antibody Manufacturing Facility Located in Brooklyn Park, Minnesota) 13-Mar-2008 Corporate Asset Purchase Buildings and Property
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

Genmab ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

23.4 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Genmab’s complete esg history, request access »

Genmab Exits (2)

Genmab’s most recent exit was on 21-Jul-2020 from CureVac. The exit was categorized as with 4 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
CureVac 21-Jul-2020 Completed
  • 4 buyers
Paradigm Therapeutics. 09-Dec-2002 Early Stage VC Completed
  • 4 buyers
To view Genmab’s complete exits history, request access »

Genmab Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Merus Utrecht, Netherlands 2003

Genmab FAQs

  • When was Genmab founded?

    Genmab was founded in 1999.

  • Where is Genmab headquartered?

    Genmab is headquartered in Valby, Denmark.

  • What is the size of Genmab?

    Genmab has 3,244 total employees.

  • What industry is Genmab in?

    Genmab’s primary industry is Biotechnology.

  • Is Genmab a private or public company?

    Genmab is a Public company.

  • What is Genmab’s stock symbol?

    The ticker symbol for Genmab is GMAB.

  • What is the current stock price of Genmab?

    As of 20-Nov-2026 the stock price of Genmab is $508.98.

  • What is the current market cap of Genmab?

    The current market capitalization of Genmab is $31.4B.

  • What is Genmab’s current revenue?

    The trailing twelve month revenue for Genmab is $4.3B.

  • Who are Genmab’s competitors?

    Arcus Biosciences, Vor Biopharma, Adaptimmune Therapeutics, Alector, and Symphogen are some of the 74 competitors of Genmab.

  • What is Genmab’s annual earnings per share (EPS)?

    Genmab’s EPS for 12 months was $11.91.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process